The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells

Acta Pharmacologica Sinica

Volumn 30, Issue 7, 2009, Pages 956-964

  Rodrigues, Alice Cristina ^a   Curi, Rui ^a   Genvigir, Fabiana Dalla Vecchia ^a   Hirata, Mario Hiroyuki ^a   Hirata, Rosario Dominguez Crespo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atorvastatin; Caco 2 cells; Drug transporters; HepG2 cells; Simvastatin

Indexed keywords

ABC TRANSPORTER; ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 1; SIMVASTATIN;

ABCB 1 GENE; ABCC 2 GENE; ABCG 2 GENE; ARTICLE; CELL STRAIN CACO 2; CELL STRAIN HEPG2; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG ADMINISTRATION ROUTE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCLO 1 B1 GENE; SLC 22 A1 GENE; SLCO 2 B1 GENE;

ANIMALS; CACO-2 CELLS; CELL LINE, TUMOR; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEMBRANE TRANSPORT PROTEINS; PYRROLES; RNA, MESSENGER; SIMVASTATIN;

EID: 67651174481     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.85     Document Type: Article

References (49)

1. Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 2005; 22: 1559-77.
2. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-28.
3. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91-8.
4. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-Coa reductase inhibitors with ABCB1, ABCC2, and OAtP1B1. Drug Metab Dispos 2005; 33: 537-46.
5. Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the protonmonocarboxylic acid co-transporter. Pharm Res 2000; 17: 209-15.
6. Rodrigues AC, Curi R, Britto LR, Rebbechi IM, Hirata MH, Bertolami MC, et al. Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells. Biochim Biophys Acta 2006; 1760: 1866-73.
7. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000; 157: 1575-80.
8. Maliepaard M, Scheffer GL, Faneyte IF, Van Gastelen MA, Pijnenborg AC, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61: 3458-64.
9. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-8.
10. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classifcation system. Pharm Res 2005; 22: 11-23.
11. Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003; 4: 393-8.
12. Chandra P, Brouwer KL. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 2004; 21: 719-35.
13. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al. A novel human hepatic organic anion transporting polypeptide (OAtP2). Identification of a liver-specific human organic anion transporting polypeptide and identifcation of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274 37161-8.
14. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 2001; 297: 861-7
15. Bolego C, Poli A, Cignarella A, Catapano AL, Paoletti R. Novel statins pharmacological and clinical results. Cardiovasc Drugs Ther 2002 16: 251-7
16. Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, et al Association between a frequent allele of the gene encoding OAtP1B1 and enhanced LDL-lowering response to fuvastatin therapy. Pharmacogenomics 2008; 9: 1217-27
17. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 2003; 306: 703-8
18. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver Gastroenterology 2001; 120: 525-33
19. Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol ther 2006; 80: 607-20
20. Englund G, Rorsman F, Ronnblom A, Karlbom U, Lazorova L, Grasjo J et al. Regional levels of drug transporters along the human intestina tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 2006; 29: 269-77
21. Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit, JW, et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 2001; 21: 5471-7
22. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and fow cytometry. J Immunol Methods 1991; 139 271-9
23. Vandesompele J, De Preter K, Pattyn F Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034
24. Schmittgen TD, Zakrajse BA, Mills AG, Gorn V, Singer MJ, Reed MW Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 2000; 285: 194-204
25. -delta;delta;;T method. Methods 2001; 25, 402-8
26. Cilla DDJr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects Clin Pharmacol ther 1996; 60: 687-95
27. Anderle P, Rakhmanova V, Woodford K, Zerangue N, Sadee W Messenger RNA expression of transporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared to human ntestines. Pharm Res 2003; 20: 3-15
28. Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, Ambudkar SV Comparison of drug transporter levels in normal colon, colon cancer and Caco-2 cells: impact on drug disposition and discovery. Mo Pharm 2006; 3: 87-93
29. Hilgers AR, Conradi RA, Burton PS. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 1990; 7: 902-10.
30. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O. Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 2006; 28: 109-17.
31. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007; 35: 1333-40.
32. Kanebratt KP, Andersson TB. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 2008; 36: 1444-52.
33. Mohammadi A, Macri J, Newton R, Romain T, Dulay D, Adeli K. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler Thromb Vasc Biol 1998; 18: 783-93.
34. Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphateglucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 2006; 79: 206-17.
35. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 2007; 99: 1706-13.
36. Bernsdorf A, Giessmann T, Modess C, Wegner D, Igelbrink S, Hecker U, et al. Simvastatin does not infuence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol 2006; 61: 440-50.
37. Niemi M, Arnold KA, Backman JT, Pasanen MK, Godtel-Armbrust U, Wojnowski L, et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 2006; 16: 801-8.
38. Denk GU, Soroka CJ, Mennone A, Koepsell H, Beuers U, Boyer JL. Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology 2004; 39: 1382-9.
39. Dias V, Ribeiro V. The expression of the solute carriers NTCP and OCt-1 is regulated by cholesterol in HepG2 cells. Fundam Clin Pharmacol 2007; 21: 445-50.
40. Pasanen MK, Fredrikson H, neuvonen PJ, niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007; 82: 726-33.
41. Kobayashi K, Yamanaka Y, Iwazaki N, Nakajo I, Hosokawa M, Negishi M, et al. Identifcation of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos 2005; 33: 924-9.
42. Kocarek TA, Dahn MS, Cai H, Strom SC, Mercer-Haines NA. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab Dispos 2002; 30: 1400-5.
43. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 2001; 276: 33309-12.
44. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002; 277: 2908-15.
45. Ebert B, Seidel A, Lampen A. Identifcation of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 2005; 26: 1754-63.
46. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006; 34: 1756-63.
47. Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther 2006; 80: 440-56.
48. Maeda T, Hirayama M, Higashi R, Sato M, Tamai I. Characterization of human OATP2B1 (SLCO2B1) gene promoter regulation. Pharm Res 2006; 23: 513-20.
49. Stedman CA, Liddle C, Coulter SA, Sonoda J, Alvarez JG, Moore DD, et al. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc Natl Acad Sci USA 2005; 102: 2063-8.